Merck ROA - Return on Assets 2010-2025 | MKKGY

Merck return on assets for the quarter ending March 31, 2025 was 5.59.

  • Merck average return on assets for 2024 was 5.44, a 10.67% increase from 2023.
  • Merck average return on assets for 2023 was 6.09, a 13.74% decline from 2022.
  • Merck average return on assets for 2022 was 7.06, a 13.5% decline from 2021.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

Merck ROA - Return on Assets 2010-2025 | MKKGY

  • Merck average return on assets for 2024 was 5.44, a 10.67% increase from 2023.
  • Merck average return on assets for 2023 was 6.09, a 13.74% decline from 2022.
  • Merck average return on assets for 2022 was 7.06, a 13.5% decline from 2021.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.5B
Zoetis (ZTS)$68B
Daiichi Sankyo, - (DSNKY)$46.9B
Takeda Pharmaceutical (TAK)$46.6B
BeOne Medicines - (ONC)$32.5B
Sandoz Group AG (SDZNY)$26.5B
Summit Therapeutics (SMMT)$20.5B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$11.1B
Stevanato Group S.p.A (STVN)$8.5B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B